Chemotherapy dose reductions in obese patients with colorectal cancer
Open Access
- 6 June 2011
- journal article
- research article
- Published by Elsevier BV in Annals Of Oncology
- Vol. 23 (3), 748-753
- https://doi.org/10.1093/annonc/mdr277
Abstract
In cancer patients with a large Body Surface Area, chemotherapy drug doses are often reduced, as studies have suggested that their pharmacokinetics may be altered. However, this strategy may result in underdosing obese patients. In three Medical Research Council trials of chemotherapy for advanced colorectal cancer, dose reductions were not mandated. This provided the opportunity to compare the toxicity levels in those obese patients fully dosed and to investigate if those under dosed experienced a worse survival. Body Mass Index (BMI) was used to classify patients as normal weight (BMI < 25), overweight (BMI 25–29), or obese (BMI 30+). Of the 4781 patients, 2158 (45%) were classified as normal weight, 1753 (37%) as overweight, and 870 (18%) as obese. There was no evidence that, in those patients fully dosed, obese patients experienced more toxicity or that dose-reducing obese patients resulted in less toxicity. However, there was a suggestion that those obese patients who were given reduced doses had a worse progression-free survival [hazard ratio (HR) 1.21, 95% confidence interval (CI) 1.06–1.39, P = 0.006] and a slightly worse overall survival (HR 1.12, 95% CI 0.96–1.30, P = 0.152). These results, although not a randomised comparison, do not support the policy of reducing chemotherapy doses for obese patients with colorectal cancer.This publication has 19 references indexed in Scilit:
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the ObeseJournal of Clinical Oncology, 2007
- Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trialThe Lancet, 2007
- Capecitabine (Cap) and oxaliplatin (Ox) in elderly and/or frail patients with metastatic colorectal cancer: The FOCUS2 trialJournal of Clinical Oncology, 2007
- Body Mass Index and Outcomes in Patients Who Receive Adjuvant Chemotherapy for Colon CancerJNCI Journal of the National Cancer Institute, 2006
- Impact of Body Mass Index on Outcomes and Treatment-Related Toxicity in Patients With Stage II and III Rectal Cancer: Findings From Intergroup Trial 0114Journal of Clinical Oncology, 2004
- Influence of body mass index on outcomes and treatment‐related toxicity in patients with colon carcinomaCancer, 2003
- Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distributionCancer Chemotherapy and Pharmacology, 1989
- Doxorubicin clearance in the obese.Journal of Clinical Oncology, 1988
- Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patientsCancer Chemotherapy and Pharmacology, 1987